UroGen Pharma Ltd (NASDAQ:URGN) traded at $13.11 at last check on current trade day and made an upward move of 6.93% on its previous day’s price.
Looking at the stock we see that its previous close was $12.26 and the beta (5Y monthly) reads 1.119 with the day’s price range being $12.15 – $13.53. In terms of its 52-week price range, URGN has a high of $20.70 and a low of $10.60. The company’s stock has gained about 2.10% over that past 30 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
UroGen Pharma Ltd has a market cap of $552.06 million and is expected to release its quarterly earnings report on 2024-Nov-12. Estimates by analysts give the company expected earnings per share (EPS) of -0.83, with the EPS growth for the year raised at -3.37 for current year and -3.37 for next year.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 24.57M, with a low of 23.16M and a high of 26.4M. The median projection represents growth squeezing down to 17.80% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 94.46M, or 14.20% up from figures reported last year.
On the other hand, looking at the outlook for the URGN stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell.
Based on estimates by 7 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the UroGen Pharma Ltd (URGN) stock as a Hold, while 5 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 3.09% off its SMA20 and -3.22% from its 50-day simple moving average. The RSI (14) is pointing at 52.03 while the volatility over the past week is 9.35% and jumps to 5.94% over the past one month. The beta value is 1.12, while the average true range (ATR) is currently pointing at 0.83. The average price target for the stock over the next 12 months is $40, with the estimates having a low of $22 and a high of $60. These price ends are -67.81% and -357.67% off the today’s price level respectively, although investors could be excited at the prospect of a -205.11% if the URGN share price touches on the median price of $40.
Coming back to UroGen Pharma Ltd (NASDAQ:URGN), we note that the average 3-month trading volume was 543.64K, while that of the preceding 10-day period stands at 0.82 million. Current shares outstanding are 42.11 million.
The insiders hold 9.30% of the company’s shares while institutions hold 98.01%. The data shows that short shares as of 2024-09-30, stood at 7.07 million at a short ratio of 13.09. This represents a 1719.00 short interest in shares outstanding on 2024-09-30. Shares short rose in September from the previous month at 6.44 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -12.60% down in year-to-date price movement.
